Verrica amends Torii deal: $8M milestone accelerated, $10M on Japan approval, $40M trial funding

Verrica Pharmaceuticals Inc.

Torii pays $8M milestone in July 2025 for starting global Phase 3 common warts trial of YCANTH.
Torii to pay $10M cash upon Japanese approval of YCANTH for molluscum, expected by end-2025.
Torii funds first $40M of trial costs (~90% of budget); Verrica repays via future royalties/transfer price.
First patient dosing in U.S. Phase 3 common warts trial expected Q4 2025.
OrbiMed waived going-concern qualification requirement under credit agreement for remainder of 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.